Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arcutis Biotherapeutics, Inc.
< Previous
1
2
Next >
Arcutis to Report Third Quarter 2023 Financial Results
October 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
October 20, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Pricing of $100 Million Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Proposed Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
October 13, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
October 06, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
September 27, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
September 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
September 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
September 12, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
September 07, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Present at Upcoming Investor Conference
September 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
August 31, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
August 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Appoints Interim Chief Financial Officer (CFO)
August 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
August 10, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report Second Quarter Financial Results
July 24, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
July 17, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Present at Upcoming Investor Conference
June 06, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
May 02, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
April 28, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Report First Quarter Financial Results
April 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
April 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
April 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
March 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
March 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
February 21, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
ARQT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.